thioguanine-anhydrous and Kidney-Diseases

thioguanine-anhydrous has been researched along with Kidney-Diseases* in 4 studies

Reviews

1 review(s) available for thioguanine-anhydrous and Kidney-Diseases

ArticleYear
The renal toxicity of cancer chemotherapeutic agents.
    Cancer treatment reviews, 1982, Volume: 9, Issue:1

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Azacitidine; Cisplatin; Cyclophosphamide; Dacarbazine; Humans; Kidney Diseases; Methotrexate; Mitomycins; Naphthacenes; Nitrosourea Compounds; Plicamycin; Streptozocin; Thioguanine

1982

Trials

1 trial(s) available for thioguanine-anhydrous and Kidney-Diseases

ArticleYear
Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients.
    Kidney international, 1996, Volume: 50, Issue:3

    To delineate the pathogenesis of the reduction in hemoglobin occurring in renal transplant patients treated with angiotensin converting enzyme inhibitors (ACEI) and azathioprine (AZA) a controlled, prospective trial of ACEI withdrawal was conducted. The ACEI was replaced by nifedipine or clonidine in 15 kidney transplant patients immunosuppressed with AZA and prednisone (enalapril in 14 and captopril in 1). Before and during 10 to 12 weeks after withdrawal of the ACEI, AZA metabolites, renal function parameters and hematological parameters including erythropoietin and reticulocytes were evaluated. Enalaprilat levels were measured and compared with 15 similar patients matched for transplant function and enalapril dosage immunosuppressed with cyclosporine and prednisone. AZA metabolites did not differ significantly in the presence or absence of the ACEI. Enalaprilat levels also showed no significant difference between the two patient groups treated with AZA or cyclosporine. Hematocrit and hemoglobin increased significantly from 37.5 +/- 6.4 to 39.7 +/- 3.6% (mean +/- SD, P = 0.02) and 12.8 +/- 2.2 to 13.5 +/- 1.2 g/dl, P = 0.04, respectively, 10 to 12 weeks after ACEI treatment had been discontinued. Simultaneously numbers of reticulocytes and erythropoietin concentrations rose significantly after 2, 4 and 10 weeks, with a peak at two weeks (from 14.1 +/- 3.8 to 20.6 +/- 8.0/1000, P < 0.05 and from 14.3 +/- 12.4 to 29.3 +/- 54.5 mU/ml, P < 0.05, respectively). In conclusion, ACEI-related anemia in renal transplant recipients seems to be due to the erythropoietin-lowering effect of this group of drugs. A pharmacokinetic interaction between AZA and enalapril is not likely since plasma enalaprilat levels were independent of the immunosuppressive regimen and AZA metabolite levels were unchanged in the presence and absence of the ACEI. Several mechanisms by which angiotensin converting enzyme blockade may cause a decrease in circulating erythropoietin are discussed.

    Topics: Adult; Anemia; Angiotensin-Converting Enzyme Inhibitors; Azathioprine; Cyclosporine; Drug Interactions; Enalaprilat; Erythrocytes; Erythropoietin; Female; Hematocrit; Hemoglobins; Humans; Immunosuppressive Agents; Kidney Diseases; Kidney Transplantation; Male; Middle Aged; Prospective Studies; Thioguanine

1996

Other Studies

2 other study(ies) available for thioguanine-anhydrous and Kidney-Diseases

ArticleYear
British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011.
    The British journal of dermatology, 2011, Volume: 165, Issue:4

    Topics: Abnormalities, Drug-Induced; Adult; Aged; Azathioprine; Bone Marrow Diseases; Chemical and Drug Induced Liver Injury; Child; Cost-Benefit Analysis; Drug Administration Schedule; Drug Approval; Drug Costs; Drug Hypersensitivity; Drug Interactions; Female; Genetic Testing; Humans; Immunosuppressive Agents; Infections; Kidney Diseases; Lactation; Male; Methyltransferases; Nausea; Neoplasms; Off-Label Use; Patient Education as Topic; Pregnancy; Risk Factors; Skin Diseases; Thioguanine; Virus Diseases

2011
The significance of focal sclerotic lesions of glomeruli in children.
    The Journal of pediatrics, 1976, Volume: 88, Issue:5

    To establish the relationship between the type of focal sclerotic lesion of glomeruli and the development of progressive renal disease, the clinical courses of 20 children with focal segmental and 7 with focal global sclerosis were analyzed. Only five patients, all of them with focal segmental sclerosis, did not have the nephrotic syndrome, although all had proteinuria. Results suggest that patients with focal global sclerosis have a course identical to that of children with the minimal lesion form of nephrotic syndrome: onset in early childhood, response to steroid therapy, and a relapsing, nonprogressive course. Focal segmental sclerosis, in constrast, is characterized by older age at onset, high incidence of nephritic symptoms, lack of response to steroid therapy, and a progressive course with histologic and functional deterioration. Since most published reports have not distinguished between these two entities, a more favorable prognosis in focal segmental sclerosis may be inferred than is actually the case.

    Topics: Adolescent; Child; Child, Preschool; Cyclophosphamide; Female; Glomerular Filtration Rate; Humans; Immunoglobulins; Infant; Kidney Diseases; Kidney Glomerulus; Male; Nephrosclerosis; Nephrotic Syndrome; Prednisone; Prognosis; Proteinuria; Thioguanine

1976